Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 6/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.48 |
| ▸ | CHRNG | P07510 | 2/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.47 |
| ▸ | NPY4R | P50391 | 7/20 | 0.47 |
| ▸ | NPY1R | P25929 | 6/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13347257 | 0.84 | TLR2 (0.56) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL12680258 | 0.84 | TLR2 (0.56) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14903000 | 0.83 | GLP1R (0.49) | ALBCHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL13371966 | 0.82 | GLP1R (0.48) | ALB | |
| SCHEMBL45887 | 0.79 | GLP1R (0.57) | ALB | |
| SCHEMBL13347258 | 0.78 | TLR2 (0.49) | CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14037925 | 0.78 | FOLH1 (0.47) | ALB | |
| SCHEMBL13347272 | 0.77 | GLP1R (0.48) | — | |
| SCHEMBL14012491 | 0.77 | FOLH1 (0.46) | ALB | |
| SCHEMBL26428992 | 0.76 | NPY4R (0.49) | NPY5RNPY4RNPY1RNPY2RGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273325-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-09-25 | — | — | US | disclosed |
| US-8273325-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-09-25 | — | — | US | disclosed |
| US-20100111865-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
| US-20100111865-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111865-A1 | CONTRAST AGENTS | CSGALNACT1, HPSE, SERPINC1 | ALB 988/4885CHRND 4368/4885CHRNA1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.